Immunotherapy and chemo before surgery for colorectal cancer with liver mets
Part of Cancer, Digestive system clinical trials.
This study tests a new drug (ivosimab, an immunotherapy) combined with chemotherapy given before surgery for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors to make surgery easier and improve the chance of removing all cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 75 years
- Colorectal cancer that has spread only to the liver (liver mets)
- The liver tumors are removable with surgery (and possibly heat/cold ablation) leaving no signs of cancer
- You have not had chemotherapy, radiation, or other cancer treatment for the liver mets before
- Your overall health is good enough for surgery and chemo (good blood counts, liver and kidney function)
- You agree to use contraception if needed during and for 3 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a new drug called ivonescimab combined with chemotherapy for people with metastatic colorectal cancer that has not spread to the liver. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This trial is for people with colorectal cancer that has spread to the liver. It tests whether adding a new drug (sotevtamab) to standard chemotherapy (FOLFOX) before surgery can help shrink tumors and improve outcomes.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
Hear when a new Colorectal Cancer With Liver Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.